At ANCON, our mission is to develop innovative, inexpensive, and non-invasive technology to screen and diagnose a full range of diseases in their earliest stages.

ANCON Medical has developed a revolutionary technology called Nanoparticle Biomarker Tagging (NBT) that enables medical professionals to detect Cancer and other diseases in a patient’s breath and introduces a promising solution in the effort to stop the spread of disease at a very early stage.

The company is currently undertaking a new financial opportunity. With this fundraise, ANCON is seeking a total of $6.5 million in equity funding at a pre-money valuation of $25.6 million in this current round.


Canterbury, Kent, United Kingdom

Minneapolis, Minnesota, USA

Please download the current investment document for the current Stage A investment opportunity by clicking the links below.

Download Power Point version:ANCON Medical Investment Deck- PPT

Download PDF version:ANCON Medical Investment Deck PDF

NBT Technology Video